Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-018-0647-z
Abstract: Background and ObjectivePaliperidone palmitate 3-monthly (PP3M) injectable formulation offers an advantage of improved medication adherence and lower relapse risk in patients with schizophrenia. This post hoc analysis compared outcomes following PP3M versus paliperidone palmitate 1-monthly… read more here.
Keywords: ris pali; treatment; pali; exposure ... See more keywords